Healthcare Providers Archives

Transforming Diabetes Management: A Step Forward with Abbott’s FreeStyle Libre CGMs and Glooko

At Glooko, we are committed to simplifying diabetes insights and management for people living with diabetes and healthcare providers alike. That’s why our platform is compatible with more than 200 diabetes and health monitoring devices and growing.

As a company, we could not be more pleased to share that we recently expanded our capabilities to integrate with Abbott’s FreeStyle Libre CGMs in the United States. This integration brings glucose data to more clinics and health systems in our all-in-one solutions for diabetes management.

This milestone is more than just a technological advancement — it’s about empowering people with Type 1, Type 2, and gestational diabetes, as well as prediabetes, to become active owners in their health. By combining the precision of Abbott’s FreeStyle Libre CGMs with Glooko’s comprehensive platform, we can provide people living with diabetes and their care teams, including endocrinologists and nurses, with a unified, holistic view of diabetes management and irrefutable information.

TFrom glucose trends to lifestyle behaviors like diet and physical activity, this latest integration ensures that critical insights are easily accessible when and where they are needed most. For healthcare providers and health systems, this means the ability to seamlessly access and analyze patients’ CGM data through Glooko and established electronic health record (EHR) solutions, more informed decision-making, and improved patient outcomes. For people living with diabetes, it means greater confidence in their care and health.

As the number of people with diabetes continues to grow, the need for seamless, data-driven solutions has never been greater. Our new integration with Abbott’s FreeStyle Libre CGMs represents a significant step forward in delivering better, more connected care. This partnership is sure to have a positive impact on the millions of people who rely on FreeStyle Libre CGMs and Glooko.

Transforming Diabetes Care in the United Kingdom: Shaping the Future through Technology, Data, and Partnerships

In the United Kingdom, diabetes technology has rapidly advanced over the past two decades, with platforms like Glooko playing a central role in simplifying care and management.

In honor of Diabetes Week U.K. (9 June to 15), we’re taking a look at the state of diabetes, technology designed to better manage the condition, and the outlook on the evolution of diabetes care and technology.

The State of Diabetes in the United Kingdom

Diabetes is a significant public health concern in the U.K. According to Diabetes U.K., more than 5.8 million people are currently living with the condition. Of these, approximately 4.6 million have been diagnosed and an estimated 1.3 million people may be living with undiagnosed Type 2 diabetes.

Of those diagnosed with diabetes in the U.K., Type 2 diabetes accounts for approximately 90% of cases. While risk factors for Type 1 diabetes include family history and the presence of other autoimmune conditions, Type 2 diabetes risk is heightened obesity, family history, a history of gestational diabetes, specific medications, and other factors.

To address the growing prevalence of diabetes and support those affected, the National Health Service (NHS) offers various education programs aimed at empowering individuals with the knowledge and skills necessary to manage their diabetes effectively, improve health outcomes, and reduce the risk of complications.

For individuals with Type 2 diabetes, programs like DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) and the X-PERT Diabetes Programme provide education on managing the condition through lifestyle changes and self-monitoring. For those with Type 1 diabetes, the DAFNE (Dose Adjustment For Normal Eating) program offers guidance on insulin management and dietary considerations and Digibete helps young people, families, and communities better manage Type 1 diabetes. Additionally, the VICTOR program is designed for adults with Type 2 diabetes who are on insulin therapy and focuses on adjusting insulin doses in response to routine changes.

Diabetes Technology Today

In the U.K., diabetes technology is advancing quickly with Glooko helping streamline data management across compatible diabetes and health monitoring devices, including:

Hybrid closed loop (HCL) systems, which combine continuous glucose monitoring (CGM) with insulin pumps to automatically adjust insulin delivery based on real-time data.
Devices like Tandem t:slim X2 require cable downloads, while mylife Loop powered by CamAPS® FX and Omnipod® 5 use cloud-to-cloud integration.
CGMs provide glucose trends and alerts and are often compatible with pumps and cloud platforms.
Abbott FreeStyle Libre CGMs data can be seen within Glooko through the upload of data from HCL-compatible insulin pumps.
Fitness and health monitoring apps can track steps, weight, and blood pressure.
Smart pens and connected pens allow for remote or in-clinic dose tracking.

Transforming Diabetes Care in the United Kingdom with Glooko

Across the country, more than 85,000 people living with diabetes use Glooko’s digital health platform to manage their diabetes and more than 500 clinics are using Glooko to provide better care to their patients.*

Through our data*, we identified key metrics for time in range for people with Type 1, Type 2, and gestational diabetes in the U.K. using Glooko during 2024.

Type	Time In Range (TIR) \| 3.9-10 mmol/l	Time in Tight Range (TITR) \| 3.9-7.8 mmol/l
Type 1 Diabetes	64%	41%
Type 2 Diabetes	58%	34%
Gestational Diabetes	74%	50%

Today, there is an increased interest in TITR and TIR as a result of the recent technology available for managing diabetes. The Glooko diabetes data management platform helps healthcare providers monitor TIR and TITR to improve glycemic outcomes for people living with diabetes, bringing data from multiple devices into one platform with comprehensive charts and graphs. It ensures consistent data access — even without connected devices — and meets high standards for data protection, including GDPR compliance, to support safe, effective, and standardised diabetes care.

The Future of Diabetes Care in the United Kingdom

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

Progress also depends on strong partnerships with leading diabetes organisations like the Diabetes Technology Network (DTN-UK) and Diabetes National Networking Forums (NNF).

By showcasing technologies such as hybrid closed loop systems at local events from these leading organisations and through initiatives like our Academy program, a collaboration between Glooko and the Association of British Clinical Diabetologists(ABCD)/DTN-UK providing free education for medical professionals in the U.K., we help educate, support, and empower both clinicians and people living with diabetes across the country.

*Internal Glooko data; based on active Glooko users that synced during 2024

New Glooko Web 25.1 and Mobile 6.11 Release Enhances Reporting and Security

As part of our ongoing commitment to supporting healthcare providers and people living with diabetes, we’re excited to share the latest enhancements and features now available in Glooko Web 25.1 and Mobile 6.11. These updates are designed to streamline workflows, improve patient engagement and security, and provide care teams with more robust tools to manage diabetes care effectively.

Patient Notes and Medications in Week View

Care teams and people living with diabetes can now view notes and medication entries added to the Glooko Mobile and Web App directly in Week View, both online and in PDF reports. These entries appear in a new collapsible “Events” section below each day, making it easier to contextualize trends in glucose data and treatment behaviors.

Streamlined Week View PDF Reports

In our new release, Week View PDFs are now cleaner and more efficient. Sections without data will be automatically hidden, allowing more patient data over a few days to fit on each page.

The glucose and statistics sections will always remain, and a single, comprehensive legend will now appear at the end of the report.

Smarter Defaults in the PDF Wizard for Hybrid Closed Loop Systems

Designed to streamline reporting workflows and help care teams quickly access the most meaningful insights, the Glooko PDF Wizard now automatically pre-selects the most relevant reports, including Summary, Week, Daily, and Devices, when a patient uses a Hybrid Closed Loop System like Omnipod® 5, Tandem t:slim X2 with Control-IQ technology, or mylife Loop powered by CamAPS® FX.

Care teams can still customize the selections as needed.

Enhanced Security in the Glooko Mobile App

At Glooko, we’re committed to the security and safety of our platform users.

People living with diabetes, including those under age 18, can now manage their login credentials (email and password) through a new Login Security section in the Glooko Mobile App’s Account Settings. We’ve also expanded support for two-factor authentication (2FA) to users to ensure an extra layer of protection.

Explore More Updates

For more detailed information about the new features designed to simplify diabetes management, be sure to check out the full release notes on the Glooko Support Center.

Helping Combat Clinician Burnout through EHR Integrations

At Glooko, we empower healthcare providers with the tools and insights they need to make informed decisions quickly and easily to improve the health outcomes of their patients living with diabetes.

With nearly half of physicians reporting at least one burnout symptom in a recent study from the American Medical Association, it’s critical we make diabetes data management simpler to not overburden those providing care.

That’s why the Glooko platform integrates with leading electronic health record (EHR) systems in the U.S., including Epic, Oracle Health, MEDITECH, Greenway Health, eClinicalWorks, NextGen, and AthenaHealth, making our diabetes management platform seamlessly and securely available within this critical healthcare technology and eliminating the need to platform switch.

Why EHR Integrations Matter

Diabetes care is complex, and healthcare providers face the challenge of managing patient data across multiple systems. In an era where time is precious and clinicians are already spending much of their time on administrative tasks, clinicians need timely access to the most relevant health data without the inefficiencies of navigating multiple data platforms.

By integrating Glooko into EHRs, we streamline how healthcare providers access diabetes data, enabling them to provide the highest quality care. Our integrations provide clinicians and care teams with immediate access to comprehensive data from more than 200 diabetes and health monitoring devices used by their patients, eliminating the need for additional logins and manual data entry by people living with diabetes each day.

EHR integrations not only optimize existing systems, but they also have the potential to enhance clinical decision-making by giving clinicians the full picture of a person’s health. It empowers them to make faster, more informed treatment decisions. That’s why health systems spend $2.5 million to $1.2 billion on EHR integrations each year. They’re powerful and their care teams can reap the benefits of reduced documentation burden.

How It Works

By leveraging SMART on FHIR technology and HL7, standard interoperability frameworks, Glooko integrates with existing EHR systems at hospitals and health systems. Healthcare providers can then access patients’ timely glucose data, medication logs, activity levels, food intake, and much more without leaving the EHR.

The integrations support healthcare systems by offering a single, unified view of a person’s diabetes information, all while ensuring secure, HIPAA-compliant data exchange. The technology is designed to streamline workflows, making it easier for clinicians to focus on what truly matters: providing quality care for their patients.

A Step Toward the Future of Diabetes Care

Following the COVID-19 pandemic, clinical teams who provide care to the more than 38 million people in the U.S. living with diabetes have greatly declined in number, furthering the urgent need for seamless, data-driven solutions to help reduce administrative burdens and workloads that drive burnout.

Since 2022, more than 138,000 nurses left the workforce due to stress, burnout, and retirement. New data from the NCSBN reveals almost 40% of nurses intend to leave the workforce by 2029, leaving the remaining time-pressed nurses to provide care to an already large patient population.
Based on a recent GoodRx study, more than 70% of U.S. counties don’t have an endocrinologist and the number of trained endocrinologists is declining, meaning primary care providers must be knowledgeable in diabetes management and shoulder the workload.
There is a significant shortfall of certified diabetes care and education specialists (CDCES), impacting diabetes care quality. In the U.S., there are about 19,500 diabetes educators — roughly 1 CDCES per 1,000 individuals with diabetes. An additional 35,000 educators would be required to meet the current demands of patients in the U.S. alone, furthering the workload burden.

And the burnout by clinicians and care teams is only going to grow greater as 98 million American adults have prediabetes, according to the CDC.

By optimizing and integrating with leading EHR systems, Glooko is taking a significant step forward in transforming diabetes management and reducing extra steps taken by healthcare providers to improve the quality of care. Our integrations help improve workflows, limit platform switching, simplify clinical decision-making, and support better outcomes for both healthcare providers and people with diabetes.

These integrations represent our ongoing commitment to delivering cutting-edge, interoperable solutions that empower both clinical teams and patients in making diabetes easier to manage.

Ready to Learn More?

Healthcare providers and hospital systems can access EHR integrations by reaching out to our dedicated team for a demo. With robust support from our dedicated team, some integrations, like with Epic, can be up and running within a weeks, making it easier than ever to take advantage of the benefits Glooko has to offer.

To learn more about Glooko’s many EHR integrations, visit our Integration Portal.

How Glooko is Transforming Diabetes Care: My First Six Months as CEO

Over the past several months since stepping into the role of CEO at Glooko, I’ve been reflecting on the incredible progress we’ve made, and the immense opportunities that lie ahead. Each day has reaffirmed my belief that our mission to transform diabetes care is both urgent and achievable. I’m more energized than ever to guide Glooko toward a future where we deliver an even greater impact for people with diabetes and those who care for them.

When I think about the future of diabetes care, one word comes to mind: transformation. Across the globe, health systems, clinicians, and people living with diabetes are looking for a holistic approach, one that brings together cutting-edge technology, patient-centric insights, and secure, scalable solutions. At Glooko, we’ve made it our mission to deliver exactly that.

Our Vision: Transforming Diabetes Care

We believe in transforming diabetes care by making it simpler, more connected, and fundamentally centered on people with diabetes. This vision underpins every decision we make, whether we’re enhancing our platform’s EHR integration, partnering with global device manufacturers, or expanding our footprint in new markets.

Our Mission: Simplifying Care and Strengthening Connections

At Glooko, we say: “We simplify care, strengthen connections, and together create a brighter future for people living with diabetes, healthcare providers, and caregivers.”

Simplify Care

We hear time and again about fragmented workflows and siloed data, forcing providers and patients to juggle multiple device platforms (mobile and web), apps, and logins. Our platform intends to change this, meaning clinicians can potentially spend less time on administrative tasks and more time where they’re needed most: caring for patients and focused on improving outcomes.

Strengthen Connections

We also see the power of community and shared decision-making. Through Glooko, patients, caregivers, and healthcare teams can collaborate more effectively, share real-time data, and gain insights that drive meaningful change in care plans. We aim to reduce the cognitive burden of diabetes data and decision making.

In my view, these are the five biggest differentiators that make Glooko stand out:

Patient First Mindset: Everything we do revolves around putting patients first. We collaborate closely with clinicians, caregivers, and people living with diabetes to ensure our technology meets real-world needs.
Commitment to Quality and Security: From ISO 27001 to HiTrust and SOC 2 Type 2 certifications, our platform is backed by enterprise-grade security and rigorously tested reliability. We understand that healthcare data is precious and that trust is earned through quality.
Innovation That Matters: Our platform is more than a “data upload tool.” It’s an engine designed to support clinical decision making. Whether it’s EHR interoperability or automated patient nudges, we constantly push boundaries to develop meaningful solutions that scale globally.
High-Performance Culture: Within the company, we’re building a talented, global team that challenges the status quo. This energy fuels our drive to expand into new markets, partner with industry leaders, and improve access to diabetes care around the world.
Better Together: Collaboration is in our DNA, and that includes partnerships with device manufacturers, healthcare providers and hospital systems. By joining forces with stakeholders across the healthcare ecosystem, we have the opportunity to create value that benefits everyone, especially people living with diabetes.

Scaling for the Future

Our work has already touched millions of lives, but we’re just getting started. With rising rates of diabetes worldwide, the need for an integrated, secure, and human-centered solution has never been greater. That’s why we’re investing in global expansion, forging new alliances, and refining our platform to make sense of the high volume of data in diabetes care.

Scaling effectively also means staying true to our roots. Our commitment to patient outcomes, uncompromising quality, and secure innovation will remain the bedrock of Glooko’s growth. As we continue to expand, our North Star will always be the same: transforming diabetes care on a global scale and making diabetes easier to manage for everyone in the diabetes care ecosystem.

A Commitment to People Living with Diabetes, Above All

Behind every data point or device upload is a person managing a complex, life-altering condition. We never lose sight of that human element. As Glooko grows, our Patients First value continues to guide us toward solutions that truly make a difference, reducing clinical burdens, improving outcomes, and helping people with diabetes live fuller, healthier lives.

MKT-0532 01

Top 3 Things You Don’t Want to Miss from Glooko at ADCES23

If you’re planning to attend the Association of Diabetes Care & Education Specialists’ ADCES23 in Houston, Team Glooko wants to meet you at booth #1101 to share the latest updates to our digital health technologies.

Some of the exciting activities that you can expect from us at the meeting:

1. Product Demos: We’ll provide live demos of the recently redesigned Glooko® Mobile App, available now in the App Store and Google Play Store. The sleek, new design improves onboarding for patients with diabetes and makes it even easier for them to input, view and understand their health data.
2. Ask An Expert: Our booth will host experienced clinicians who will share how their clinics and patients are benefitting from Glooko’s connected care platforms and achieving better health outcomes. Experts at these informal sessions include:
  - Gary Scheiner, MS, CDCES, Integrated Diabetes Services (Friday: 9 to 10 a.m.; Saturday: 11:30 a.m. to 12:30 p.m.) He will cover data analysis and interpretation for a variety of devices, including CGMs, insulin pumps and AID systems. Gary will walk through the various Glooko reports he relies on for different patients and the insights they provide.
  - Susan Weiner, RDN, CDCES, Susan Weiner Nutrition (Friday: 11:30 a.m. to 12:30 p.m.; Saturday: 9 to 10 a.m.) She will review how best to support patients in their self-care by leveraging and incorporating Glooko into their daily lives. She’ll also review various functionalities within the Glooko Mobile App and what she likes most about them from a patient engagement and user experience standpoint.
  - Allison Nimlos, LMFT, CDCES, Greater Than Counseling & Coaching (Saturday: 2:30 to 3:30 p.m.) She will focus on the psychosocial aspects of diabetes care management, including how data can be both empowering and anxiety inducing. Allison will discuss how she onboards newly diagnosed patients by leveraging the app’s different data visualization tools to best support the patient’s mental well-being and desired behavioral changes.
  - Bridget Wood, RD, LD, CDCES, Glooko (Friday: 10 to 11:30 a.m.; Sunday: 9 to 11 a.m.) She will discuss how she uses Glooko as a person living with Type I diabetes. Bridget will also share how to enhance a virtual diabetes coaching practice using the health data in the Glooko Mobile App from both the provider and patient experiences.
3. Food Tracker: People with diabetes can use the innovative food tracker feature of the Glooko® Mobile App to easily log their food intake, view their food data alongside data from compatible diabetes and health monitoring devices, medications and insulin, and keep a historical account of how food affects their chronic condition.

Be sure to also check out our blog series from Glooko’s very own experts.

With maintaining a healthy meal plan to keep blood glucose levels in target range being important, take some time to explore healthy eating and living tips designed for people with diabetes from Bridget Wood, RD, LD, CDCES.
Curious about the many benefits of physical activity for people with diabetes and how to get started with an exercise program? Explore ‘Move More’ from Sanaz Nosrat, PhD, CSCS, ACE PT.

See you in Houston!

MKT-0479 01

Glooko Showcases its Connected Care Solutions that Improve Health Outcomes at the American Diabetes Association (ADA) 83rd Scientific Sessions

At the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, Team Glooko was thrilled to connect with so many old and new friends on the tradeshow floor and during industry events.

During the conference, our team showcased how our innovative connected care platforms for people living with diabetes and their healthcare providers improve health outcomes. We also provided live demos of the Glooko® Mobile App, which has a sleek new design that makes diabetes management even easier. The redesign boasts improved patient onboarding and streamlined data visualizations that allow for easy inputting, viewing and understanding of health data.

At our booth, we hosted “Ask an Expert” where leading clinicians, including University of Missouri-Kansas City School of Medicine’s Mark Clements, MD PhD CPI FAAP, Cleveland Clinic’s Dr. M. Cecilia Lansang, Rady Children’s Hospital’s Dr. Carla Demeterco-Berggren and Integrated Diabetes Services’ Gary Scheiner, shared how their clinics and patients benefit from the Glooko connected care platforms. The expert clinicians also discussed Glooko’s EHR integration, patient engagement, remote care and population health capabilities with attendees.

Representatives from Dexcom, one of our many device partners, visited our booth to share how their continuous glucose monitors (CGMs) work with our platform for improved diabetes management.

On the tradeshow floor, our team talked with some users of our connected care platforms to hear how Glooko has positively impacted their clinics. Here’s what they said:

We were also a proud sponsor of the sold-out Summer 2023 DiabetesMine D-Data ExChange, where we held live demos of Glooko. The event was packed with informative and inspiring discussions on the latest developments in diabetes technology.

We look forward to showcasing our latest digital health innovations next year at ADA 2024 in Orlando!

MKT-0473 01

Glooko Showcases Its Connected Care Innovations and Strong Partnerships at ATTD 2023

At the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin, Team Glooko had the exciting opportunity to meet new and old friends on the tradeshow floor and offer live demonstrations of the innovative Glooko and Glooko XT connected care platforms at our stand.

And the conference was all about our partnerships with leading global diabetes companies.

We hosted Dexcom, Novo Nordisk and Tandem in our stand to demonstrate how the Glooko platform works with their products for people living with diabetes and their care teams. We also joined these three industry partners in their stands to demonstrate how the Glooko connected care platform works with their digital health innovations and devices.

We announced our new partnership with Sanofi, which gives people with diabetes more choices in customizing their diabetes management by integrating the SoloSmart® cap for SoloStar® insulin pens with the Glooko connected care platform. This new integration will help improve insulin management and tracking, while supporting insulin dosing data.

While we already support an extensive and growing list of diabetes and health monitoring devices, Team Glooko met with over 45 of our partners to discuss how to bring more digital health solutions to healthcare providers.

Our poster presentation, “Remote Patient Monitoring and Glycemic Control Trends During the COVID-19 Pandemic,” highlighted the effectiveness of our remote care platform’s capabilities when healthcare delivery needed to rapidly shift due to stay-at-home orders, but clinicians needed to remain engaged and provide care to their patients with diabetes.

We were also a proud sponsor of the diaTribe Foundation and ATTD’s panel discussion, “Solvable Problems in Diabetes,” with leading experts around continuous glucose monitoring, time in range and associated therapeutic and data-driven interventions for people living with diabetes.

After an action-packed few days, our team is already looking forward to showcasing our latest innovations next year at ATTD 2024 in Florence.

MKT-0429 01

Glooko Demonstrates Better Diabetes Management and Outcomes Through Clinical Studies

At Glooko, we improve the health outcomes of people with diabetes and related chronic conditions through our personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and healthcare providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials.

Through multiple clinical studies conducted, we’ve observed immediate and sustained improvements across multiple glycemic outcomes following remote patient monitoring (RPM). These findings show that RPM provides multiple clinical benefits and improved outcomes for people with diabetes.

Some of the highlights of our real-world data studies include:

Delivering Improved and Sustained Glycemic Control^1,2,3
Use of the Glooko Mobile App Improving Glycemic Outcomes in 2 Months⁴
Declining Patient Outcomes 6-8 Weeks After Stopping Using Glooko⁵

Download the infographic (PDF) below for findings from our studies.

1. Sheng T et al. Glycemic Improvements Following Mobile-Enabled Remote Patient Monitoring: A Randomized Control Study, ADA Scientific Sessions, June 2020. 2. Clements M, Duffee J and McCarther D. Remote patient monitoring for adults with type 2 diabetes. ADCES Research Sessions, August, 2020. 3. Sheng T, Parks L and Clements M. Remote patient monitoring in the real world: Immediate and long-term improvements in glycemic control. American Association of Diabetes Educators (AADE) Annual Meeting, Houston TX. August, 2019. 4. Offringa R et al. Digital diabetes management application improves glycemic outcomes in people with type 1 and type 2 diabetes. Journal of diabetes science and technology, 12(3), 701-708. 2018. 5. Sheng T et al. Mobile-Enabled Food Logging is Associated with Improved Glycemic Management in the Real World. Diabetes Technology Meeting (DTM), 2019. 6. Abad R et al. Use of mobile-enabled reminders feature is associated with improved behavioral and glycemic outcomes in the real world. American Diabetes Association (ADA), Scientific Sessions, 2019. 7. Babikian S et al. Deteriorating Glucose Control in Patients with Diabetes after Disengagement from a Mobile Health App. Diabetes Technology Meeting, Poster, 2020.

MKT-0084 01

Glooko Unveils Positive Remote Patient Monitoring Data at the 2022 IDF World Diabetes Congress

Glooko, a leading provider of intelligent, connected care solutions and remote patient monitoring (RPM) for people with diabetes and related chronic conditions, presented positive data from two recent studies on remote patient monitoring at the 2022 IDF World Diabetes Congress.

The first study presented by Team Glooko at the Congress, Cost and Outcomes of a Diabetes Remote Patient Monitoring System: A Simulation Analysis, was the company’s inaugural study using a health economics and outcomes research (HEOR) simulation model. In a randomized controlled trial of RPM and digital therapeutics (DTx), the intervention resulted in significantly improved HbA1c in patients with type 2 diabetes (T2D). Incorporating these results into a microsimulation model of longer-term complications, mortality and costs demonstrated the potential for RPM and DTx to elicit health gains and cost savings among people with diabetes.

The second study presented by Team Glooko, The Impact of Remote Patient Monitoring on Glycated Hemoglobin for Type 2 Diabetes: A Randomized Controlled Trial, demonstrated that a comprehensive 24-week RPM diabetes management program was more effective in improving HbA1c compared to usual care for adults with T2D.

These studies further showcase the clinical and economic benefits of the Glooko platform, which is sold to healthcare providers globally, and available for free as a mobile app to patients.

Team Glooko will continue to highlight the benefits of our connected care platform for diabetes and related chronic conditions at industry events in 2023.

MKT-0413 01

Glooko Blog

Category: Healthcare Providers